Telegram to Distribute Grok in $300 Million xAI Deal, CEO Durov Says
Telegram agreed to a one-year deal with Elon Musk's xAI to distribute its Grok chatbot to the messaging platform's billion-plus users, according to Chief Executive Officer Pavel Durov.
The app will receive $300 million in cash and equity from xAI, as well as 50% of revenue from subscriptions to the artificial intelligence chatbot sold via Telegram, Durov said in a post on X Wednesday.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
18 minutes ago
- Associated Press
Zealand Pharma submits Marketing Authorization Application to the European Medicines Agency for glepaglutide in short bowel syndrome
Press release – No. 10 / 2025 Zealand Pharma submits Marketing Authorization Application to the European Medicines Agency for glepaglutide in short bowel syndrome Copenhagen, Denmark, June 2, 2025 – Zealand Pharma A/S (Nasdaq: ZEAL) ('Zealand') (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announced the submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for glepaglutide, a long-acting GLP-2 analog, for the treatment of adult patients with short bowel syndrome (SBS). The submission of the MAA to the EMA for glepaglutide administered twice weekly for the treatment of SBS is based on results from a pivotal Phase 3 trial (EASE-1), supported by interim results from two ongoing long-term extension trials (EASE-2 and EASE-3) and results from a mechanistic trial (EASE-4). 'We are pleased to bring our potential best-in-class GLP-2 analog, glepaglutide, one step closer to patients in Europe living with short bowel syndrome with intestinal failure, who urgently need more effective and more convenient treatment options,' said David Kendall, MD, Chief Medical Officer of Zealand Pharma. 'We believe that glepaglutide, administered twice weekly, offers meaningful potential to reduce both the burden of parenteral support and the inconvenience of daily dosing required with the only currently available GLP-2 therapy. Looking ahead, we expect to initiate the EASE-5 Phase 3 trial in the second half of the year to obtain further confirmatory safety and efficacy data on the twice weekly dosing regimen, supporting regulatory submission in the U.S.' About glepaglutide Glepaglutide is a long-acting GLP-2 analog in development as a potential treatment option for short bowel syndrome (SBS). Glepaglutide is developed as a liquid product in an autoinjector designed for subcutaneous administration by twice weekly dosing, aimed to reduce, or eliminate, the need for parenteral support in people living with SBS. The U.S. Food and Drug Administration (FDA) has granted orphan drug designation for glepaglutide for the treatment of SBS. About the EASE Clinical Trial Program The Phase 3 program, named EASE, is designed to evaluate the potential for glepaglutide to reduce or eliminate the need for parenteral support in SBS patients with intestinal failure. EASE-1 (NCT03690206) was a randomized, double-blind Phase 3 trial that enrolled a total of 106 SBS patients with intestinal failure who were dependent on parenteral support for at least three days per week. Patients were evenly randomized to receive treatment with 10 mg glepaglutide administered either once or twice weekly, or placebo. The primary endpoint in the trial was the absolute change in weekly parenteral support volume from baseline at 24 weeks. At 24 weeks, glepaglutide administered twice weekly significantly reduced the total weekly volume of PS by 5.13 liters/week, compared to a reduction of 2.85 liters/week in the placebo group (p=0.0039). When administered once weekly, glepaglutide treatment resulted in a reduction in weekly PS of 3.13 liters/week, however this did not achieve statistical significance. A total of 9 patients treated with glepaglutide were completely weaned off PS (achieving enteral autonomy), while no placebo-treated patients were able to discontinue PS. For patients treated with glepaglutide twice weekly, 14% of patients (n=5) achieved enteral autonomy. In total, 102 of 106 participating patients completed EASE-1, of which 96 continued into the ongoing two-year, long-term safety and efficacy extension trial, EASE-2. EASE-2 (NCT03905707) is a randomized, double-blind trial in which SBS patients continued their randomly assigned treatment from EASE-1 with glepaglutide 10 mg once- or twice-weekly. Patients who received placebo in EASE-1 were re-randomized to treatment with either glepaglutide 10 mg once- or twice-weekly. In an interim analysis conducted after at least six months of treatment, clinical response to glepaglutide across the key efficacy endpoints was generally maintained or showed continued improvement, including additional patients on both doses weaning off PS. Patients who complete EASE-2 are eligible to participate in EASE-3 (NCT04881825), evaluating glepaglutide administered once weekly using an autoinjector. An interim analysis of EASE-3, conducted with the first 57 patients rolled over from EASE 2, showed that the reduction in prescribed PS was generally maintained. EASE-4 (NCT04991311) was a Phase 3b trial to assess mechanistic effects of glepaglutide on intestinal fluid and energy uptake. The trial provides evidence of the pharmacodynamic effects of glepaglutide in improving intestinal absorption. In the second half of 2025, Zealand Pharma expects to initiate EASE-5, a single Phase 3 clinical trial that is anticipated to provide further confirmatory evidence for a regulatory submission in the U.S. About Zealand Pharma A/S Zealand Pharma A/S (Nasdaq: ZEAL) ('Zealand') is a biotechnology company focused on the discovery and development of peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market and three candidates are in late-stage development. The company has development partnerships with a number of pharma companies as well as commercial partnerships for its marketed products. Zealand was founded in 1998 and is headquartered in Copenhagen, Denmark, with a presence in the United States. For more information about Zealand's business and activities, please visit Forward looking statements This press release contains 'forward-looking statements', as that term is defined in the Private Securities Litigation Reform Act of 1995 in the United States, as amended, even though no longer listed in the United States this is used as a definition to provide Zealand Pharma's expectations or forecasts of future events regarding the research, development and commercialization of pharmaceutical products, the timing of the company's pre-clinical and clinical trials and the reporting of data therefrom. These forward-looking statements may be identified by words such as 'aim,' 'anticipate,' 'believe,' 'could,' 'estimate,' 'expect,' 'forecast,' 'goal,' 'intend,' 'may,' 'plan,' 'possible,' 'potential,' 'will,' 'would' and other words and terms of similar meaning. You should not place undue reliance on these statements, or the scientific data presented. The reader is cautioned not to rely on these forward-looking statements. Such forward-looking statements are subject to risks, uncertainties and inaccurate assumptions, which may cause actual results to differ materially from expectations set forth herein and may cause any or all of such forward-looking statements to be incorrect, and which include, but are not limited to, unexpected costs or delays in clinical trials and other development activities due to adverse safety events, patient recruitment or otherwise; unexpected concerns that may arise from additional data, analysis or results obtained during clinical trials; our ability to successfully market both new and existing products; changes in reimbursement rules and governmental laws and related interpretation thereof; government-mandated or market-driven price decreases for our products; introduction of competing products; production problems at third party manufacturers; dependency on third parties, for instance contract research or development organizations; unexpected growth in costs and expenses; our ability to affect the strategic reorganization of our businesses in the manner planned; failure to protect and enforce our data, intellectual property and other proprietary rights and uncertainties relating to intellectual property claims and challenges; regulatory authorities may require additional information or further studies, or may reject, fail to approve or may delay approval of our drug candidates or expansion of product labeling; failure to obtain regulatory approvals in other jurisdictions; exposure to product liability and other claims; interest rate and currency exchange rate fluctuations; unexpected contract breaches or terminations; inflationary pressures on the global economy; and political uncertainty. If any or all of such forward-looking statements prove to be incorrect, our actual results could differ materially and adversely from those anticipated or implied by such statements. The foregoing sets forth many, but not all, of the factors that could cause actual results to differ from our expectations in any forward-looking statement. All such forward-looking statements speak only as of the date of this company announcement and are based on information available to Zealand Pharma as of the date of this announcement. We do not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. Information concerning pharmaceuticals (including compounds under development) contained within this material is not intended as advertising or medical advice. Contacts Adam Lange (Investors) Vice President, Investor Relations [email protected] Neshat Ahmadi (Investors) Investor Relations Manager [email protected] Anna Krassowska, PhD (Investors and Media) Vice President, Investor Relations & Corporate Communications [email protected]
Associated Press
18 minutes ago
- Associated Press
Circus SE Moves Global Headquarters to Munich
MUNICH--(BUSINESS WIRE)--Jun 2, 2025-- Circus SE (XETRA: CA1 ), a global technology company in AI software and autonomous robotics for the food service industry, today announces the relocation of its global headquarters to Munich, marking a strategic move to strengthen its position in one of Europe's most dynamic technology hubs. With a strong foundation already laid in the region through years of mechanical engineering and robotics development, the company is doubling down on Munich as its core location for AI innovation, advanced robotics, and pre-series production of its new CA-M military-grade autonomous robot platform. 'As OpenAI, NVIDIA and other global leaders invest in Munich and the global demand for intelligent automation surges, Munich has become one of the few places in the world where cutting-edge research meets world-class engineering talent,' said Nikolas Bullwinkel, CEO and Founder of Circus. 'We're building the future of robotics here – from our civilian food service automation to next-gen defense solutions – and Munich will be our long-term launchpad.' The new HQ will serve as a central R&D hub, attracting top talent and enabling closer collaboration with leading universities, research centers, and the region's industrial base. 'The ecosystem in Munich is continuously evolving into a global hotspot for robotics and AI,' says Dr. Arne Rost, member of the Circus Advisory Board Member and Managing Director of the Venture Lab Robotics/AI from the Technical University Munich. 'The city brings together academic excellence, entrepreneurial drive, and international deep-tech talent – and Circus is one of the most ambitious companies actively shaping this ecosystem.' Circus' expansion signals a broader trend of global tech players choosing Munich as their base to scale high-impact innovation. With serial production underway and global deployments of its robotics system CA-1 lined up, Circus is set to redefine how intelligent machines integrate into everyday life — and Munich is where that future begins. About Circus SE Circus SE (XETRA: CA1) is a global technology company in the field of embodied AI and AI software for the food service industry, driving innovation and autonomy in labor-intensive sectors. With its core product, the CA-1 robot, Circus is a pioneer in applying embodied AI, integrating cutting-edge technologies into real-world operations, and transforming the food service industry. By combining advanced robotics, AI-driven software, and a mission to solve global challenges, Circus is shaping the future of autonomous systems and redefining human-AI collaboration. Headquartered in Germany and with a rapidly growing international presence, Circus leads the next generation of AI applications. View source version on CONTACT: Hongkongstrasse 6 20457 Hamburg [email protected] KEYWORD: GERMANY EUROPE INDUSTRY KEYWORD: TECHNOLOGY ENGINEERING MANUFACTURING SOFTWARE HARDWARE ROBOTICS IOT (INTERNET OF THINGS) FOOD TECH ARTIFICIAL INTELLIGENCE SOURCE: Circus SE Copyright Business Wire 2025. PUB: 06/02/2025 02:52 AM/DISC: 06/02/2025 02:50 AM
Associated Press
18 minutes ago
- Associated Press
Colt, Honeywell and Nokia join forces to trial space-based quantum-safe cryptography
Press Release Colt, Honeywell and Nokia join forces to trial space-based quantum-safe cryptography 2 June 2025 Espoo, Finland – Colt Technology Services (Colt), a global digital infrastructure company, Honeywell and Nokia today announced a collaboration to explore quantum-safe networking using satellite communications. As part of the initiative, the companies are planning to test new ways of protecting encrypted optical network traffic from risks presented when quantum computing potentially breaks through traditional encryption methods, leaving data vulnerable to cyber threats. Traditional encryption methods, or cryptography, rely on complex mathematical problems that are difficult for computers to solve, but quantum computers are expected to solve these problems faster, potentially breaking through traditional encryption methods and putting data at risk. One promising advancement in this field is quantum key distribution (QKD), a technology central to the quantum evolution. However, QKD currently faces a major limitation: terrestrial physical constraints restrict its range to around 100 kilometers. To achieve global coverage of QKD, the technology can overcome these limitations by moving into space. Colt, Honeywell and Nokia plan to explore quantum-safe cryptography, trialling space-based and subsea techniques which are resistant to quantum computing attacks. The companies will trial quantum key distribution - a method used to securely share encryption keys between two parties – using low earth orbit satellites for ultra-long distances and transatlantic reach. The three companies share a collective goal: enable customers to benefit from the huge potential of quantum computing in ways that help solve pressing challenges, while protecting them from risk. The trial is expected to be of interest to organisations responsible for vast amounts of highly sensitive data such as financial firms, healthcare and pharmaceutical organisations and government bodies. 'Fundamental to the collaboration between Colt, Honeywell and Nokia is a shared passion and determination to push the boundaries of technology to find solutions which safeguard our customers and help them succeed. At Colt, we do everything we can to make life easier for our customers. It's why we're taking action now to protect our customers from future cybersecurity risks, tackling tomorrow's threats, today,' said Buddy Bayer, chief operating officer, Colt Technology Services. 'With over five decades of aerospace expertise, Honeywell has witnessed and adapted to the evolution of the global communications landscape. We are proud to continue as a leader in innovating future-proof solutions such as the QEYSSat and QKDSat missions for the quantum era. This collaboration represents a significant step forward in securing the future of critical data: designing solutions to enhance resilience, ensuring long-term data security for critical infrastructure and communications systems,' said Lisa Napolitano, vice president and general manager, Space, Honeywell Aerospace Technologies. 'Nokia is helping our customers stay ahead when it comes to securing critical data through resilient defense-in-depth strategies. Quantum computing brings great promise, but it's also a potential threat to the encryption models on which society has relied so far. This collaboration with Colt and Honeywell shows how space-based quantum-safe technologies can help protect networks, safeguarding sensitive information across every domain against future quantum threats,' said James Watt, vice president and general manager, Optical Networks at Nokia. Ahead of the trial, Colt, Honeywell and Nokia have drafted a white paper with more detail on the risks, threats and opportunities presented by quantum cryptography. The paper, entitled 'The Journey to Quantum-Safe Networking' is available to download here. The announcement follows a pilot Colt announced in March to explore quantum-secure networking across terrestrial networks. Multimedia, technical information and related news Web Page: Quantum Explained Web Page: Quantum Safe Technologies About Nokia At Nokia, we create technology that helps the world act together. As a B2B technology innovation leader, we are pioneering networks that sense, think and act by leveraging our work across mobile, fixed and cloud networks. In addition, we create value with intellectual property and long-term research, led by the award-winning Nokia Bell Labs, which is celebrating 100 years of innovation. With truly open architectures that seamlessly integrate into any ecosystem, our high-performance networks create new opportunities for monetization and scale. Service providers, enterprises and partners worldwide trust Nokia to deliver secure, reliable and sustainable networks today – and work with us to create the digital services and applications of the future. About Colt Technology Services Colt Technology Services (Colt) is a global digital infrastructure company which creates extraordinary connections to help businesses succeed. Powered by amazing people and like-minded partners, Colt is driven by its purpose: to put the power of the digital universe in the hands of its customers, wherever, whenever and however they choose. Since 1992, Colt has set itself apart through its deep commitment to its customers, growing from its heritage in the City of London to a global business spanning 40+ countries, with over 6,000 employees and more than 80 offices around the world. Colt's customers benefit from expansive digital infrastructure connecting 32,000 buildings across 230 cities, more than 50 Metropolitan Area Networks and 275+ Points of Presence across Europe, Asia, the Middle East, Africa and North America's largest business hubs. Privately owned, Colt is one of the most financially sound companies in the sector. Obsessed with delivering industry-leading customer experience, Colt is guided by its dedication to customer innovation, by its values and its responsibility to its customers, partners, people and the planet. About Honeywell Products and services from Honeywell Aerospace Technologies are found on virtually every commercial, defense and space aircraft, and in many terrestrial systems. The Aerospace Technologies business unit builds aircraft engines, cockpit and cabin electronics, wireless connectivity systems, mechanical components, power systems, and more. It's hardware and software solutions create more fuel-efficient aircraft, more direct and on-time flights and safer skies and airports. For more information, visit or follow Honeywell Aerospace Technologies on LinkedIn. Honeywell is an integrated operating company serving a broad range of industries and geographies around the world. Our business is aligned with three powerful megatrends – automation, the future of aviation and energy transition – underpinned by our Honeywell Accelerator operating system and Honeywell Forge IoT platform. As a trusted partner, we help organizations solve the world's toughest, most complex challenges, providing actionable solutions and innovations through our Aerospace Technologies, Industrial Automation, Building Automation and Energy and Sustainability Solutions business segments that help make the world smarter and safer as well as more secure and sustainable. For more news and information on Honeywell, please visit Media inquiries Nokia Press Office Email: [email protected] Sarah Miller - Nokia media relations Phone: 613-720-9716 | Email: [email protected] Colt Head of PR Anne Amlot Email: [email protected] Honeywell Juliet Collins-Achong Phone: +44 7787 282932 Email: [email protected] Follow Nokia on social media LinkedInXInstagramFacebookYouTube Follow Colt on social media LinkedInInstagramTikTokFacebook
